{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-098404","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2025-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.506487+00:00","generated_at":"2026-05-17T04:10:40.401529+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Carisma Therapeutics to be delisted from Nasdaq on Oct 13; expects to wind down operations","bullets":["Received Nasdaq delisting letter; common stock suspended from trading effective Oct 13, 2025; no appeal planned.","Approval received to list common stock on OTCID market tier under symbol CARM starting Oct 13, 2025.","Company expects to pursue sale or monetization of remaining assets and orderly wind down of operations.","Warns that it is unlikely there will be meaningful cash available for distribution to stockholders.","May file Form 15 to suspend SEC reporting obligations after delisting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-098404","json":"https://secwatch.observer/filing/0001104659-25-098404.json","markdown":"https://secwatch.observer/filing/0001104659-25-098404.md","text":"https://secwatch.observer/filing/0001104659-25-098404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/tm2528458d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:10:40.401529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4d9522e41d7543182a0261874dfae5fc41caacf","claim":"Carisma Therapeutics Inc. received a nasdaq delisting notice notice regarding other.","evidence_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025. The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities and Exchange Commissio","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","confidence":0.97}],"comparable_filings":[{"accession":"0001213900-26-059270","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-05-20T12:49:08+00:00","headline":"Tether International acquires SoftBank's stake in Twenty One Capital; board members resign","event_type":"other_material","sec_items":["1.02","3.01","5.02","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-059270","json":"https://secwatch.observer/filing/0001213900-26-059270.json","markdown":"https://secwatch.observer/filing/0001213900-26-059270.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/ea0291071-8k_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","comparable_excerpt":"o independent directors, the minimum number required during the transition period\nfor compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm"}},{"accession":"0001493152-26-024495","ticker":"SOPA","company_name":"SOCIETY PASS INCORPORATED.","filed_at":"2026-05-20T10:05:33+00:00","headline":"Society Pass receives Nasdaq delisting notice after filing Chapter 11 bankruptcy","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024495","json":"https://secwatch.observer/filing/0001493152-26-024495.json","markdown":"https://secwatch.observer/filing/0001493152-26-024495.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/0001493152-26-024495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","comparable_excerpt":"May 14, 2026, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nthat Nasdaq had determined to delist the Company’s common stock, par value $0.0001 per share (the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1817511/000149315226024495/0001493152-26-024495-index.htm"}},{"accession":"0001193125-26-230708","ticker":"BTM","company_name":"Bitcoin Depot Inc.","filed_at":"2026-05-19T20:01:24+00:00","headline":"Bitcoin Depot files Chapter 11; Nasdaq to suspend BTM stock and warrants on May 26","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.95,"calibrated_materiality_score":0.95,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-230708","json":"https://secwatch.observer/filing/0001193125-26-230708.json","markdown":"https://secwatch.observer/filing/0001193125-26-230708.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/0001193125-26-230708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/d228011d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","comparable_excerpt":"May 18, 2026, the Company received a letter from the Listing Qualifications Department staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Debtors’ commencement of the Chapter 1","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1901799/000119312526230708/0001193125-26-230708-index.htm"}},{"accession":"0001437749-26-016538","ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-05-13T12:03:45+00:00","headline":"Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB","event_type":"other_material","sec_items":["3.01","8.01"],"materiality_score":1.0,"calibrated_materiality_score":1.0,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016538","json":"https://secwatch.observer/filing/0001437749-26-016538.json","markdown":"https://secwatch.observer/filing/0001437749-26-016538.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/rvph20260512_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","comparable_excerpt":"May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm"}},{"accession":"0001437749-26-016455","ticker":"BKYI","company_name":"BIO KEY INTERNATIONAL INC","filed_at":"2026-05-12T20:46:03+00:00","headline":"BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.95,"calibrated_materiality_score":0.95,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016455","json":"https://secwatch.observer/filing/0001437749-26-016455.json","markdown":"https://secwatch.observer/filing/0001437749-26-016455.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/0001437749-26-016455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/bkyi20260512_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","comparable_excerpt":"May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/0001437749-26-016455-index.htm"}},{"accession":"0001213900-26-062844","ticker":"ADTX","company_name":"Aditxt, Inc.","filed_at":"2026-05-29T20:21:24+00:00","headline":"Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062844","json":"https://secwatch.observer/filing/0001213900-26-062844.json","markdown":"https://secwatch.observer/filing/0001213900-26-062844.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/ea0292786-8k_aditxt.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","comparable_excerpt":"May 27, 2026, Aditxt, Inc. (the “Company”)\nreceived a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s\nQuarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum\nstockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)\n(the “Stockholders’ Equity Requirement”). The Letter further","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm"}},{"accession":"0001104659-26-066974","ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-05-27T20:30:41+00:00","headline":"Liminatus Pharma receives Nasdaq delisting notice; appeals filed","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066974","json":"https://secwatch.observer/filing/0001104659-26-066974.json","markdown":"https://secwatch.observer/filing/0001104659-26-066974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/tm2615785d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","comparable_excerpt":"May 20, 2026, the Company received a notice\nfrom Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will\nbe delisted from The Nasdaq Global Mark","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm"}},{"accession":"0001213900-26-061113","ticker":"EMAT","company_name":"Evolution Metals & Technologies Corp.","filed_at":"2026-05-26T21:28:49+00:00","headline":"Evolution Metals regains Nasdaq compliance after late 10-Q filing; notice resolved","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061113","json":"https://secwatch.observer/filing/0001213900-26-061113.json","markdown":"https://secwatch.observer/filing/0001213900-26-061113.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026061113/0001213900-26-061113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026061113/ea0292140-8k_evolution.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm","comparable_excerpt":"May 21, 2026, Evolution Metals & Technologies\nCorp. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The\nNasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026061113/0001213900-26-061113-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}